drugset / Trial / NCT03892434
Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy of sequential therapy with intravitreal dexamethasone implant followed by bevacizumab compared with bevacizumab monotherapy for macular edema (ME) secondary to retinal vein occlusion (RVO).
Timeline
- Start
- 2019-03-18
- Primary completion
- 2019-12-18
- Completion
- 2020-06-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 1.25 mg | Intravitreal |
| Comparator | Dexamethasone | Small molecule | 0.75 mg | Intravitreal |